Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

SCANDINAVIAN MEDICARE ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 8.7% 8.7%   Bankruptcy risk   1.5% 1.0% 1.1% 1.7% 1.6% 2.6% 7.2% 7.1%   Credit score (0-100)   77 88 83 71 74 61 33 34   Credit rating   A A A A A BBB BBB BBB   Credit limit (kDKK)   40.0 806.2 526.8 12.8 35.8 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   8,221 6,887 6,408 7,010 5,643 3,421 3,421 3,421   Gross profit   4,948 3,937 4,468 3,838 3,966 1,533 0.0 0.0   EBITDA   4,160 2,832 3,392 2,583 2,869 378 0.0 0.0   EBIT   4,160 2,829 3,388 2,579 2,865 374 0.0 0.0   Pre-tax profit (PTP)   3,775.5 2,936.6 3,420.4 2,923.4 2,467.4 496.7 0.0 0.0   Net earnings   2,918.1 2,259.7 2,630.0 2,249.0 1,858.3 368.2 0.0 0.0   Pre-tax profit without non-rec. items   3,776 2,937 3,420 2,923 2,467 497 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 16.0 13.0 9.0 5.0 3,211 0.0 0.0   Shareholders equity total   8,921 11,127 13,703 15,895 17,696 18,005 17,819 17,819   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   16,050 13,456 19,020 21,518 21,842 23,506 17,819 17,819   Net Debt   -6,602 -4,176 -3,632 -2,805 -2,957 -2,107 -17,819 -17,819     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   8,221 6,887 6,408 7,010 5,643 3,421 3,421 3,421   Net sales growth   6.4% -16.2% -7.0% 9.4% -19.5% -39.4% 0.0% 0.0%   Gross profit   4,948 3,937 4,468 3,838 3,966 1,533 0.0 0.0   Gross profit growth   0.2% -20.4% 13.5% -14.1% 3.3% -61.3% -100.0% 0.0%   Employees   3 3 3 3 3 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% -33.3% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   16,050 13,456 19,020 21,518 21,842 23,506 17,819 17,819   Balance sheet change%   21.1% -16.2% 41.3% 13.1% 1.5% 7.6% -24.2% 0.0%   Added value   4,159.9 2,832.3 3,392.2 2,582.7 2,868.6 377.6 0.0 0.0   Added value %   50.6% 41.1% 52.9% 36.8% 50.8% 11.0% 0.0% 0.0%   Investments   0 13 -7 -8 -8 3,202 -3,211 0   Net sales trend   2.0 -1.0 -2.0 1.0 -1.0 -2.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   50.6% 41.1% 52.9% 36.8% 50.8% 11.0% 0.0% 0.0%   EBIT %   50.6% 41.1% 52.9% 36.8% 50.8% 10.9% 0.0% 0.0%   EBIT to gross profit (%)   84.1% 71.9% 75.8% 67.2% 72.2% 24.4% 0.0% 0.0%   Net Earnings %   35.5% 32.8% 41.0% 32.1% 32.9% 10.8% 0.0% 0.0%   Profit before depreciation and extraordinary items %   35.5% 32.9% 41.1% 32.1% 33.0% 10.9% 0.0% 0.0%   Pre tax profit less extraordinaries %   45.9% 42.6% 53.4% 41.7% 43.7% 14.5% 0.0% 0.0%   ROA %   28.6% 20.6% 21.5% 14.7% 13.6% 2.8% 0.0% 0.0%   ROI %   56.1% 30.3% 28.1% 20.2% 17.5% 3.6% 0.0% 0.0%   ROE %   39.0% 22.5% 21.2% 15.2% 11.1% 2.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   55.6% 82.7% 72.0% 73.9% 81.0% 76.6% 100.0% 100.0%   Relative indebtedness %   86.7% 33.8% 83.0% 80.2% 73.5% 160.8% 0.0% 0.0%   Relative net indebtedness %   6.4% -26.8% 26.3% 40.2% 21.1% 99.2% -520.9% -520.9%   Net int. bear. debt to EBITDA, %   -158.7% -147.4% -107.1% -108.6% -103.1% -557.9% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   2.1 5.1 3.2 3.5 4.8 3.5 0.0 0.0   Current Ratio   2.1 5.1 3.2 3.5 4.8 3.5 0.0 0.0   Cash and cash equivalent   6,602.0 4,176.0 3,632.0 2,805.0 2,957.0 2,106.6 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   374.9 406.7 694.1 847.5 1,041.1 1,630.4 0.0 0.0   Trade creditors turnover (days)   480.8 68.7 360.1 244.1 34.6 234.7 0.0 0.0   Current assets / Net sales %   183.0% 172.7% 266.9% 282.7% 355.9% 557.1% 520.9% 520.9%   Net working capital   6,936.0 7,925.0 10,155.0 12,234.0 14,313.0 11,739.3 0.0 0.0   Net working capital %   84.4% 115.1% 158.5% 174.5% 253.6% 343.2% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   2,740 2,296 2,136 2,337 1,881 1,710 0 0   Added value / employee   1,387 944 1,131 861 956 189 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   1,387 944 1,131 861 956 189 0 0   EBIT / employee   1,387 943 1,129 860 955 187 0 0   Net earnings / employee   973 753 877 750 619 184 0 0